Working… Menu


The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02687035
Recruitment Status : Completed
First Posted : February 22, 2016
Results First Posted : April 8, 2021
Last Update Posted : April 8, 2021
Information provided by (Responsible Party):
Edwards Lifesciences

Brief Summary:
Following completion of enrollment in the PARTNER II SAPIEN 3 intermediate risk trial, this trial provided continued access to treatment for subjects with severe aortic stenosis who were at intermediate surgical risk.

Condition or disease Intervention/treatment Phase
Aortic Stenosis Device: SAPIEN S3 valve Not Applicable

Detailed Description:
This multi-center, single arm registry will provide continued access of the Edwards SAPIEN 3 Transcatheter Heart Valve and delivery systems to severe aortic stenosis patients at intermediate risk for standard aortic valve replacement. Patient data will be entered into the TVT Registry (TVTR) from screening through 1 year including the collection of 5 year follow-up through CMS.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1822 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves: Continued Access Program for SAPIEN 3 Intermediate Risk (S3iCAP)
Actual Study Start Date : January 2015
Actual Primary Completion Date : October 2017
Actual Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: TAVR
Intermediate risk patients receiving transcatheter aortic valve replacement (TAVR)
Device: SAPIEN S3 valve
Transcatheter aortic valve replacement
Other Names:
  • TAVR
  • TAVI
  • Transcatheter aortic valve replacement

Primary Outcome Measures :
  1. Death [ Time Frame: 30 days ]
    Number of deaths

  2. Death [ Time Frame: 1 year ]
    Number of deaths

  3. Stroke [ Time Frame: 30 days ]
    Number of participants with stroke

  4. Stroke [ Time Frame: 1 year ]
    Number of participants with stroke

  5. Aortic Valve Reintervention [ Time Frame: 30 days ]
    Number of participants with aortic valve reintervention

  6. Aortic Valve Reintervention [ Time Frame: 1 year ]
    Number of participants with aortic valve reintervention

Secondary Outcome Measures :
  1. Annular Dissection [ Time Frame: 30 days ]
    Number of participants with annular dissection

  2. Aortic Dissection [ Time Frame: 30 days ]
    Number of participants with aortic dissection

  3. Major Access Vascular Site Complication [ Time Frame: 30 days ]
    Number of participants with major vascular complications

  4. Unplanned Vascular Surgery or Intervention [ Time Frame: 30 days ]
    Number of participants with unplanned vascular surgery or intervention

  5. Retroperitoneal Bleeds [ Time Frame: 30 days ]
    Number of participants with retroperitoneal bleed

  6. Gastrointestinal Bleed [ Time Frame: 30 days ]
    Number of participants with gastrointestinal bleeding

  7. Genitourinary Bleed [ Time Frame: 30 days ]
    Number of participants with genitourinary bleeding

  8. Bleeding at Access Site [ Time Frame: 30 days ]
    Number of participants with bleeding at the access site

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must be covered by Medicare. This will enable Edwards to link to the CMS database for long term follow-up through 5 years. No other insurance provider will be accepted.
  2. Assessment of intermediate surgical risk defined as STS 4-8% or heart team assessment of intermediate risk factors.
  3. Patient has senile degenerative aortic valve stenosis with echocardiographically derived criteria: mean gradient > 40 mmHg or jet velocity greater than 4.0 m/s and an initial aortic valve area (AVA) of < 0.8 cm2 or indexed EOA < 0.5 cm2/m2. Qualifying echo must be within 60 days of the date of the procedure.
  4. Aortic valve annulus area range (273mm2-680 mm2) per 3D imaging (echo, CT, or MRI).
  5. Patient is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA Functional Class II or greater.
  6. The heart team agrees (and verified in the case review process) that valve implantation will likely benefit the patient.
  7. Heart team agrees (a priori) on treatment strategy for concomitant coronary disease (if present).
  8. The study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
  9. The study patient agrees to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which will be conducted as a phone follow-up.

Exclusion Criteria:

  1. Heart team assessment of inoperability (including examining cardiac surgeon).
  2. Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment [(defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)].
  3. Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is non-calcified.
  4. Mixed aortic valve disease (aortic stenosis and aortic re-regurgitation with predominant aortic regurgitation >3+).
  5. Pre-existing mechanical or bioprosthetic valve in any position.
  6. Complex coronary artery disease:

    1. Unprotected left main coronary artery
    2. Syntax score > 32 (in the absence of prior revascularization)
  7. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease). Implantation of a permanent pacemaker or ICD is not considered exclusion criteria.
  8. Any patient with a balloon valvuloplasty (BAV) < 30 days of the procedure (unless BAV is a bridge to procedure after a qualifying ECHO).
  9. Patients with planned concomitant surgical or transcatheter ablation for atrial fibrillation.
  10. Leukopenia (WBC < 3000 cell/mL), acute anemia (Hgb < 9 g/dL), thrombocytopenia (Plt < 50,000 cell/mL).
  11. Hypertrophic cardiomyopathy with or without obstruction (HOCM).
  12. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of screening evaluation.
  13. Need for emergency surgery for any reason.
  14. Severe ventricular dysfunction with LVEF < 20%.
  15. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
  16. Active upper GI bleeding within 3 months (90 days) prior to procedure.
  17. A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be anticoagulated for the study procedure.
  18. Native aortic annulus size < 16 mm or > 28mm as measured by echocardiogram.
  19. Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic attack (TIA) within 6 months (180 days) of the procedure.
  20. Renal insufficiency (creatinine > 3.0 mg/dL) and/or renal replacement therapy at the time of screening.
  21. Estimated life expectancy < 24 months (730 days) due to carcinomas, chronic liver disease, chronic renal dis-ease or chronic end stage pulmonary disease.
  22. Expectation that patient will not improve despite treatment of aortic stenosis.
  23. Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch atheroma [especially if thick (> 5 mm), protruding or ulcerated] or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe "unfolding" and tortuosity of the thoracic aorta. (Transfemoral)
  24. Iliofemoral vessel characteristics that would preclude safe placement of 14F or 16F introducer sheath such as severe obstructive calcification, severe tortuosity or min-imum average vessel size less than 5.5 mm. (Transfem-oral).
  25. Currently participating in an investigational drug or an-other device study. Note: Trials requiring extended fol-low-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
  26. Active bacterial endocarditis within 6 months (180 days) of procedure.
  27. Evidence of intracardiac mass, thrombus, vegetation, active infection or endocarditis.
  28. Inability to tolerate anticoagulation/antiplatelet therapy.
  29. For transfemoral approach only: Femoro-iliac vessels < 5.5 mm for the 23 mm and the 26 mm system and < 6.0 mm for the 29 mm system.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02687035

Show Show 56 study locations
Sponsors and Collaborators
Edwards Lifesciences
Layout table for investigator information
Principal Investigator: Susheel Kodali, MD University of Columbia
Principal Investigator: Vinod Thourani, MD Emory University
  Study Documents (Full-Text)

Documents provided by Edwards Lifesciences:
Study Protocol  [PDF] September 1, 2015
No Statistical Analysis Plan (SAP) exists for this study.

Layout table for additonal information
Responsible Party: Edwards Lifesciences Identifier: NCT02687035    
Other Study ID Numbers: 2010-12 S3iCAP
First Posted: February 22, 2016    Key Record Dates
Results First Posted: April 8, 2021
Last Update Posted: April 8, 2021
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Edwards Lifesciences:
Aortic stenosis
Transcatheter Heart Valve
Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Valve Stenosis
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction